IP Library Granted Patent US 8,620,596
Granted Patent B2
US 8,620,596 · App. 13/185,599 · Granted Dec 31, 2013

System and method for sorting data

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,620,596
App. No.
13/185,599
Granted
Dec 31, 2013
Kind
B2
Abstract

A method and apparatus that enables a user to sort data from one or more sample lots, which may be obtained via a network, such as the Internet, into a composite parameter structure. The composite parameter structure is a function of one or more parameters corresponding to one or more characteristics associated with one or more sample lots. The composite parameter structure representation may be printed, stored, or transmitted to another location. A server device that is coupled and working in conjunction with a client device may implement the present invention.

Claims (44)

1. A method for sorting chromatographic data comprising:

(a) providing chromatographic data related to a first sample lot and chromatographic data related to a second sample lot to a processor;

(b) using the processor to identify one or more chromatographic peaks associated with the first sample lot;

(c) using the processor to identify parameters corresponding to each of the one or more chromatographic peaks of the first sample lot;

(d) using the processor to identify one or more chromatographic peaks associated with the second sample lot;

(e) using the processor to determine whether the one or more chromatographic peaks associated with the second sample lot correspond to one or more of the parameters corresponding to the chromatographic peaks of the first sample lot;

(f) using the processor to establish one or more additional parameters corresponding to each chromatographic peak of the second sample lot that does not correspond to the parameters corresponding to the chromatographic peaks of the first sample lot;

(g) using the processor to provide the additional parameters to an output device; and

(h) using the processor to establish a composite parameter structure as a function of the parameters corresponding to the chromatographic peaks of the first sample lot and only one chromatographic peak corresponding to each of the additional parameters.

2. The method of claim 1 , wherein each peak is a function of a relative retention time.

3. The method of claim 1 , further comprising using the processor to generate a representation as a function of the first sample lot, the chromatographic peaks of the second sample lot, and the composite parameter structure.

4. The method of claim 1 , further comprising: identifying one or more chromatographic peaks associated with a third sample lot; and determining whether the one or more chromatographic peaks associated with the third sample lot correspond to one or more parameters of the composite parameter structure.

5. The method of claim 4 , further comprising modifying the composite parameter structure as a function of chromatographic peaks of the third sample lot.

6. The method of claim 1 , further comprising: identifying one or more chromatographic peaks associated with an n th -sample lot; and determining whether the one or more chromatographic peaks associated with the n th -sample lot correspond to one or more parameters of the composite structure.

7. A method for determining whether the chemical composition of a generic formulation of pregnant mare's urine corresponds to that of a reference listed drug comprising conjugated estrogens, the method comprising:

(a) creating a composite parameter structure corresponding to the reference listed drug by:

(i) providing data related to a first sample lot of the reference listed drug and data related to a second sample lot of the reference listed drug to a processor;

(ii) using the processor to identify one or more characteristics associated with the first sample lot;

(iii) using the processor to identify parameters corresponding to each of the one or more characteristics of the first sample lot;

(iv) using the processor to identify one or more characteristics associated with the second sample lot;

(v) using the processor to determine whether the one or more characteristics associated with the second sample lot correspond to one or more of the parameters corresponding to the characteristic of the first sample lot;

(vi) using the processor to establish one or more additional parameters corresponding to each characteristic of the second sample lot that does not correspond to the parameters corresponding to the characteristic of the first sample lot;

(vii) using the processor to provide the additional parameters to an output device; and

(viii) using the processor to establish the composite parameter structure as a function of the parameters corresponding to characteristics of the first sample lot and only one chromatographic peak corresponding to each of the additional parameters;

(b) comparing data related to at least one sample lot of the generic formulation to the composite parameter structure; and

(c) determining whether the chemical composition of the generic formulation corresponds to that of the reference listed drug based on the comparison in step (b).

8. The method of claim 7 , wherein at least one of the characteristics is a function of a relative retention time.

9. The method of claim 7 , wherein at least one of the characteristics is a function of atomic mass units.

10. The method of claim 7 , wherein at least one of the characteristics is a function of one or more peaks.

11. The method of claim 10 , wherein each peak is a function of a relative retention time.

12. A processing apparatus comprising a server, a network, and a client terminal, wherein:

the server comprises at least one memory, a processor, and at least one circuit; the server is adapted to transmit data to and receive data from the client terminal, via the network;

the processor is operatively connected to the memory and the circuit; and

the processor is adapted to execute program code to:

identify one or more characteristics associated with the first sample lot;

identify parameters corresponding to each of the one or more characteristics of the first sample lot;

identify one or more characteristics associated with the second sample lot;

determine whether the one or more characteristics associated with the second sample lot correspond to one or more of the parameters corresponding to the characteristic of the first sample lot;

establish one or more additional parameters corresponding to each characteristic of the second sample lot that does not correspond to the parameters corresponding to the characteristic of the first sample lot;

provide the additional parameters to an output device; and

establish a composite parameter structure as a function of the parameters corresponding to characteristics of the first sample lot and only one chromatographic peak corresponding to each of the additional parameters.

13. The processing apparatus of claim 12 , wherein the memory stores a program and a data table.

14. The processing apparatus of claim 13 , wherein the data table stores data associated with the first sample lot, data associated with the second sample lot, or the composite parameter structure.

15. The processing apparatus of claim 12 , wherein the client terminal is a desktop computer, laptop computer, personal digital assistant, wireless handheld device, or mobile phone.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067240/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0542 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Apr 6, 2021
From: BIOSPECIFICS TECHNOLOGIES LLC; PAR PHARMACEUTICAL, INC.; AUXILIUM US HOLDINGS, LLC; ASTORA WOMEN'S HEALTH, LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 055846/0246 →
SECURITY INTEREST Recorded Jun 8, 2017
From: PAR PHARMACEUTICAL, INC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 042743/0216 →
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: PAR PHARMACEUTICAL, INC.; ENDO GENERICS HOLDINGS, INC.; INNOTEQ, INC.
Reel/Frame 042171/0036 →
RELEASE OF SECURITY INTEREST Recorded Sep 30, 2015
From: BANK OF AMERICA, N.A.
To: PAR PHARMACEUTICAL, INC.; INNOTEQ, INC.; PAR PHARMACEUTICAL COMPANIES, INC.
Reel/Frame 036695/0782 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 25, 2015
From: PAR PHARMACEUTICAL, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 036687/0821 →
SECURITY AGREEMENT Recorded Oct 1, 2012
From: PAR PHARMACEUTICAL COMPANIES, INC.; PAR PHARMACEUTICAL, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 029061/0252 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2012
From: RUEMER, ROBERT; RAGUNATHAN, NARAYAN; FEMIA, PH.D., ROBERT A.
To: PAR PHARMACEUTICAL, INC.
Reel/Frame 028381/0904 →